ABCL AbCellera Biologics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1703057 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY92.1%
TTM net income YoY13.6%
TTM EPS YoY15.8%
Revenue 3-yr CAGR10.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-298.0%
Net margin-218.5%
FCF margin-48.4%
EBITDA margin-264.0%
Returns
ROE-14.6%
ROA-10.4%
ROIC (approx.)-18.2%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets29.2%
Debt / equity0.00x
Current ratio12.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue25.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $75.13M | $28.83M | $38.02M | $485.42M | $375.20M |
| R&D expense | $186.83M | $167.26M | $175.66M | $107.88M | $62.06M |
| SG&A expense | $83.23M | $85.49M | $75.18M | $55.48M | $41.85M |
| Operating income | -$217.10M | -$314.77M | -$237.21M | $216.51M | $204.41M |
| Pretax income | -$177.59M | -$200.40M | -$174.03M | $239.10M | $219.15M |
| Income tax | -$31.18M | -$37.54M | -$27.63M | $80.58M | $65.69M |
| Net income | -$146.41M | -$162.86M | -$146.40M | $158.52M | $153.46M |
| EBITDA | -$198.66M | -$302.23M | -$224.45M | $225.46M | $218.86M |
| EPS (basic) | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 |
| EPS (diluted) | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
| Weighted avg. shares (diluted) | 298.71M | 294.33M | 289.17M | 314.83M | 318.29M |
| Balance sheet | |||||
| Cash & equivalents | $128.51M | $156.32M | $158.32M | $411.54M | $501.14M |
| Receivables | $39.41M | $31.98M | $0 | — | — |
| Inventory | $6.34M | $0 | — | — | — |
| Current assets | $728.23M | $751.37M | $871.99M | $1.03B | $929.80M |
| PP&E, net | — | — | — | $217.25M | $111.62M |
| Goodwill | $47.81M | $47.81M | $47.81M | $47.81M | $47.81M |
| Intangibles | $38.38M | $42.11M | $120.42M | $131.50M | $148.39M |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B |
| Current liabilities | $64.31M | $76.61M | $119.01M | $118.32M | $120.68M |
| Total liabilities | $390.05M | $304.47M | $335.78M | $307.63M | $292.84M |
| Shareholders' equity | $966.90M | $1.06B | $1.15B | $1.23B | $1.03B |
| Shares outstanding | 300.60M | 295.76M | 290.82M | 286.85M | 283.26M |
| Cash flow statement | |||||
| Operating cash flow | -$131.29M | -$108.56M | -$43.88M | $277.36M | $244.58M |
| Capital expenditure | $42.77M | $78.40M | $76.95M | $70.66M | $58.45M |
| Free cash flow | -$174.07M | -$186.95M | -$120.82M | $206.70M | $186.13M |
| Investing cash flow | $87.75M | $121.41M | -$221.11M | -$352.62M | -$332.25M |
| Financing cash flow | $14.08M | $12.77M | $10.36M | -$1.63M | -$3.89M |
| Depreciation & amortization | $18.44M | $12.54M | $12.76M | $8.95M | $14.45M |
| Stock-based compensation | $55.79M | $67.58M | $64.18M | $49.48M | $30.65M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.